Democratising access to quantum computing: IQM Quantum Computers launches “IQM Spark” for universities and labs
IQM Quantum Computers (IQM), the European leader in building quantum computers, today launched “IQM Spark,” comprising a superconducting quantum computer and tailored learning experiences for universities and research labs worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830120669/en/
IQM Spark quantum computer (Photo: Business Wire)
IQM Spark comes pre-installed with a 5-qubit quantum processing unit, with more options available allowing for a wide variety of research experiments.
To help universities kick-start their quantum program, in addition, universities will have free maintenance for one year, and IQM will also provide training for running the system and learning materials accessible through IQM Academy, a user-friendly online platform. With IQM Spark, students of all levels (bachelor, master, and PhD) will have the opportunity to learn hands-on about quantum computing.
Additionally, universities can also provide their students with the skillset needed for a quantum-enabled future by leveraging both hardware and software within the learning materials. With its technical track record and world-class expertise, IQM is also committed to collaborating with universities to drive advancements in quantum science.
Dr. Kuan Yen Tan, Chief Technology Officer and Co-founder of IQM Quantum Computers, said: “Since our inception, we’ve invested in and promoted quantum education and the advancement of research, and it’s apparent that universities around the globe need critical tools like IQM Spark to train the workforce needed for the next generation. Given the potential of quantum computing, the ecosystem will require a wide range of talent across electronics, chip fabrication, hardware design, and software engineering. We are confident that our system will facilitate the learning experience and engage students with the physical system.”
“We’ve designed this offering for universities and research labs to build up their quantum expertise and we believe that our system will not only perform fundamental quantum experiments and raise interest in Science, Technology, Engineering, and Mathematics (STEM) but we will also advance university science around quantum computing in general, while addressing the shortage of talent and providing value for the job market,” Dr. Björn Pötter, Head of Product at IQM Quantum Computers, points out.
IQM has already delivered 5-qubit quantum computers to some universities and research institutions, including the VTT Technical Research Centre of Finland and the Leibniz Supercomputing Centre in Germany. The quantum computer at VTT has been connected to LUMI, Europe’s most powerful supercomputer, hosted by the CSC - IT Center for Science.
“VTT and IQM successfully collaborated in delivering Finland’s first quantum computer in 2021. The 5-qubit quantum computer enables users to take the first steps in developing quantum algorithms and learn how to utilise the new technology in practice”, said Pekka Pursula, Research Manager in Quantum Technologies at VTT.
“On-premises quantum hardware is only available from a very limited number of vendors. This fact alone makes it hard for us to provide this leading-edge hardware to our scientists. Pricing and missing learning resources make it even harder to make this leading-edge technology available for educational purposes for our students,” said Prof. Dr. Dieter Kranzlmüller, Chairman of the Board of Directors of the Leibniz Supercomputing Centre, which caters to all universities of Bavaria in Germany.
“IQM Spark will address three major challenges: availability, learning resources, and affordability. In that way, universities can give practical experience to the next generation of quantum computing experts,” he added.
“Making on-premises quantum computer hardware available to our scientists and students as a low-barrier resource will give a boost to scientific progress and educate the next generation of quantum experts. This paves the way for students in Bavarian universities, such as Ludwig Maximilian University of Munich (LMU) and Technical University of Munich (TUM) students, to become entrepreneurs in the field of quantum technologies and live up to the excellence claim of the Munich universities,” he concluded.
About IQM Quantum Computers:
IQM is the European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific, co-design approach. IQM’s commercial quantum computers include Finland’s first commercial 54-qubit quantum computer with VTT, IQM-led consortium’s (Q-Exa) HPC quantum accelerator in Germany, and IQM processors will also be used in the first quantum accelerator in Spain. IQM has over 280 employees with offices in Paris, Madrid, Munich, Singapore, and Espoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830120669/en/
Contact information
Sylwia Barthel de Weydenthal, Head of Marketing and Communications
Email: press@meetiqm.com
Mobile: +358505966629
www.meetiqm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom